Insight

Dec 11, 2024, 09:32

Nelson Dusetti: Our project COMBAT-PDAC has secured nearly 2 million euros in funding from the EP PerMed

Nelson Dusetti, Research Director at INSERM, shared a post on LinkedIn:

“I am thrilled to share that our international consortium has secured nearly €2 million in funding from the EP PerMed – the European Partnership for Personalised Medicine for our project COMBAT-PDAC: COMBinATorial Personalized Approaches for Subtyping and Targeting Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma.

This ambitious initiative is further supported by the ANR, the French National Research Agency, ensuring robust financial backing for the French contributions to the project.

Our COMBAT-PDAC project seeks to overcome this challenge by leveraging innovative approaches to identify and target diverse cell populations in PDAC tumors. Specifically, we aim to:

Identify and validate combinatorial biomarkers to capture the tumor’s complexity.
Develop monoclonal antibodies and CAR-T cells to target distinct PDAC subpopulations.
Investigate the role of these targets in PDAC progression to uncover novel diagnostic and therapeutic mechanisms.

This ambitious project brings together six partners from four countries:

Germany:
TU Dresden, Prof. Michele Solimena
Helmholtz-Zentrum Dresden-Rossendorf, Dr. Anja Feldmann

France:
Cancer Research Center of Marseille (INSERM U.1068), Dr. Nelson Dusetti

Italy:
Istituto Europeo di Oncologia, Dr. Gioacchino Natoli

Spain:
Fundació Institut de Recerca Biomèdica, Dr. Direna Alonso Curbelo-Curbelo
Vall d’Hebron Institute of Oncology (VHIO), Dr. Teresa Macarulla

As part of the Translational Research and Innovative Therapies group at the CRCM – Centre de Recherche en Cancérologie de Marseille and Institut Paoli-Calmettes, I am honored to collaborate with such exceptional researchers to address the unmet clinical needs in PDAC.

This multidisciplinary initiative, combining advanced omics, machine learning, functional genomics, and cutting-edge therapeutic tools, represents a significant step forward in tackling pancreatic cancer’s complexity.

Find more information here.”

“Newly funded ‘EP Permed’ project targets pancreatic cancer diversity for better diagnosis and treatment”

Nelson Dusetti: Our project COMBAT-PDAC has secured nearly 2 million euros in funding from the EP PerMed

More posts featuring Nelson Dusetti.

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.